[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627144":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":38,"centralContacts":45,"locations":54,"responsibleParty":258,"collaborators":50,"id":260,"slug":261,"hasResults":262,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":50,"eligibilityCriteria":266,"healthyVolunteers":262,"sex":267,"minAge":268,"maxAge":50,"enrollmentInfo":269,"targetDuration":50,"studyType":272,"phases":273,"briefSummary":275,"conditions":276,"keywords":284,"overallStatus":111,"whyStopped":50,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},{"fullName":5,"class":6},"Whitehawk Therapeutics, Inc.","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation - 21 Day treatment cycle","EXPERIMENTAL","Escalating doses of HWK-007 administered intravenously (IV)",[13],"Drug: HWK-007",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion Group 1- 21-day treatment cycle - non-squamous EGFR-WT NSCLC","Expanded enrolment at selected dose of HWK-007 in NSCLC.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dose Expansion Group 2 - 21-day treatment cycle - Tumor TBD","Expanded enrolment at second selected dose of HWK-007 administered intravenously (IV) in Tumor - TBD",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Dose Expansion Group 3 - 21-day treatment cycle - Tumor TBD","Expanded enrolment at third selected dose in Tumor - TBD",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Dose Expansion Group 4 - 21-day treatment cycle - Tumor TBD","Dose Expansion of HWK-007, a PTK7-directed ADC.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","HWK-007","HWK-007 is a PTK7- targeted ADC being developed for the treatment of solid tumors.",[9,15,19,23,27],[37],"HWK-007 anti-PTK7 targeted ADC",[39,43],{"name":40,"affiliation":41,"role":42},"Margaret C Dugan, MD","Whitehawk Therapeutics","STUDY_DIRECTOR",{"name":44,"affiliation":41,"role":42},"Edward C Spindler, BS, MBA",[46,52],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Clinical Trial Manager Lead","CONTACT","888-392-9025",null,"WHWK-Clinical-Trials@whitehawktx.com",{"name":53,"role":48,"phone":50,"phoneExt":50,"email":51},"Central email mailbox - Whitehawk Therapeutics",[55,76,92,109,127,144,161,180,195,210,224,240],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"University of Arkansas","NOT_YET_RECRUITING","Little Rock","Arkansas","72205-7199","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-92.28959,34.74648,{"lat":67,"lon":66},[70,74],{"name":71,"role":48,"phone":50,"phoneExt":72,"email":73},"Michael Birrer, MD","501-686-8274","MJbirrer@uams.edu",{"name":71,"role":75,"phone":50,"phoneExt":50,"email":50},"PRINCIPAL_INVESTIGATOR",{"facility":77,"status":57,"city":78,"state":79,"zip":80,"country":61,"countryCode":62,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"UCLA - Hematology\u002FOncology Clinical Research Unit","Los Angeles","California","90095",{"type":64,"coordinates":82},[83,84],-118.24368,34.05223,{"lat":84,"lon":83},[87,91],{"name":88,"role":48,"phone":89,"phoneExt":50,"email":90},"Aaron Lisberg, MD","310-352-8252","alisberg@mednet.ucla.edu",{"name":88,"role":75,"phone":50,"phoneExt":50,"email":50},{"facility":93,"status":57,"city":94,"state":95,"zip":96,"country":61,"countryCode":62,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"St. Francis Medical Center (OSF Healthcare)","Peoria","Illinois","61637",{"type":64,"coordinates":98},[99,100],-89.58899,40.69365,{"lat":100,"lon":99},[103,107],{"name":104,"role":48,"phone":105,"phoneExt":50,"email":106},"Michelle C Rowland, MD","309-308-3350","michelle.rowland@osfhealthcare.org",{"name":108,"role":75,"phone":50,"phoneExt":50,"email":50},"Michelle Rowland, MD",{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":61,"countryCode":62,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"START - Midwest","RECRUITING","Grand Rapids","Michigan","49546",{"type":64,"coordinates":116},[117,118],-85.66809,42.96336,{"lat":118,"lon":117},[121,125],{"name":122,"role":48,"phone":123,"phoneExt":50,"email":124},"Manish Sharma, MD","616-954-5554","manish.sharma@startresearch.com",{"name":126,"role":75,"phone":50,"phoneExt":50,"email":50},"Manish Sharma",{"facility":128,"status":57,"city":129,"state":130,"zip":131,"country":61,"countryCode":62,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Hackensack University Medical Center - John Theurer Cancer Center","Hackensack","New Jersey","07601",{"type":64,"coordinates":133},[134,135],-74.04347,40.88593,{"lat":135,"lon":134},[138,142],{"name":139,"role":48,"phone":140,"phoneExt":50,"email":141},"Oncology Clinical Research Referral Office","551-996-1777","oncologyresearchreferral@hmhn.org",{"name":143,"role":75,"phone":50,"phoneExt":50,"email":50},"Miguel Gonzalez, MD",{"facility":145,"status":57,"city":146,"state":147,"zip":148,"country":61,"countryCode":62,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Roswell Park Comprehensive Care Center","Buffalo","New York","14263",{"type":64,"coordinates":150},[151,152],-78.87837,42.88645,{"lat":152,"lon":151},[155,160],{"name":156,"role":48,"phone":157,"phoneExt":158,"email":159},"Bailey Fitzgerald, MD","716-845-2300","8338","bailey.fitzgerald@roswellpark.org",{"name":156,"role":75,"phone":50,"phoneExt":50,"email":50},{"facility":162,"status":57,"city":163,"state":164,"zip":165,"country":61,"countryCode":62,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"University Hospital - Cleveland Medical Center","Cleveland","Ohio","44106",{"type":64,"coordinates":167},[168,169],-81.69541,41.4995,{"lat":169,"lon":168},[172,176,178],{"name":173,"role":48,"phone":174,"phoneExt":50,"email":175},"Matthew C Mirsky, MD","301-980-8969","Matthew.Mirsky2@UHhospitals.org",{"name":177,"role":48,"phone":50,"phoneExt":50,"email":50},"C",{"name":179,"role":75,"phone":50,"phoneExt":50,"email":50},"Matthew MIrsky, MD",{"facility":181,"status":111,"city":182,"state":183,"zip":184,"country":61,"countryCode":62,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"NEXT Oncology - Austin","Austin","Texas","78758",{"type":64,"coordinates":186},[187,188],-97.74306,30.26715,{"lat":188,"lon":187},[191],{"name":192,"role":48,"phone":193,"phoneExt":50,"email":194},"Sheena Sahota, MD","737-610-5200","ssahota@nextoncology.com",{"facility":196,"status":111,"city":197,"state":183,"zip":198,"country":61,"countryCode":62,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"NEXT - Oncology - Houston","Houston","77054",{"type":64,"coordinates":200},[201,202],-95.36327,29.76328,{"lat":202,"lon":201},[205,209],{"name":206,"role":48,"phone":207,"phoneExt":50,"email":208},"Jennifer Segar, MD","832-384-7900","jsegar@nextoncology.com",{"name":206,"role":75,"phone":50,"phoneExt":50,"email":50},{"facility":211,"status":111,"city":212,"state":183,"zip":213,"country":61,"countryCode":62,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"START - San Antonio","San Antonio","78229",{"type":64,"coordinates":215},[216,217],-98.49363,29.42412,{"lat":217,"lon":216},[220],{"name":221,"role":48,"phone":222,"phoneExt":50,"email":223},"Drew Rasco, MD","210-593-5258","drew.rasco@startresearch.com",{"facility":225,"status":111,"city":226,"state":227,"zip":228,"country":61,"countryCode":62,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"NEXT Oncology - Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":64,"coordinates":230},[231,232],-77.30637,38.84622,{"lat":232,"lon":231},[235,239],{"name":236,"role":48,"phone":237,"phoneExt":50,"email":238},"Alexander Spira, MD, PhD","571-350-8400","aspira@nextoncology.com",{"name":236,"role":75,"phone":50,"phoneExt":50,"email":50},{"facility":241,"status":57,"city":242,"state":243,"zip":244,"country":61,"countryCode":62,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":64,"coordinates":246},[247,248],-122.33207,47.60621,{"lat":248,"lon":247},[251,255,256],{"name":252,"role":48,"phone":253,"phoneExt":50,"email":254},"Lei C Deng, MD","206-606-4801","ldeng1@fredhutch.org",{"name":177,"role":48,"phone":50,"phoneExt":50,"email":50},{"name":257,"role":75,"phone":50,"phoneExt":50,"email":50},"Lei Deng, MD",{"type":259,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR","100627144","phase-1-study-evaluating-the-safety-and-efficacy-of-hwk-007-a-ptk7-directed-antibody-drug-conjugate-in-participants-with-advanced-solid-tumors-100627144",false,"NCT07444814","Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\nHave one of the following solid tumor cancers:\n\n1. Monotherapy escalation and backfill cohorts:\n\n   1. non-squamous EGFR-Wt NSCLC\n   2. Endometrial carcinoma\n   3. Platinum Resistant Ovarian Cancer\n2. Monotherapy expansion cohorts:\n\n   1. Non-squamous EGFR-Wt NSCLC\n   2. Additional tumor indications to be defined in a future amendment\n\nExclusion Criteria:\n\n1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n2. Individual with history of carcinomatous meningitis\n3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n4. Individual with evidence of corneal keratopathy or history of cornea transplant\n5. Any serious unresolved toxicities from prior therapy\n6. Significant cardiovascular disease\n7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n8. History of pneumonitis\u002Finterstitial lung disease\n9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","ALL","18 Years",{"count":270,"type":271},226,"ESTIMATED","INTERVENTIONAL",[274],"PHASE1","HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.",[277,278,279,280,281,282,283],"Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Metastatic","Ovarian Cancer Metastatic Recurrent","Non-squamous EGFR Wt NSCLC","Platinum Resistant Ovarian Cancer","PROC",[285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,282,301],"PTK7","Ovarian cancer","Endometrial cancer","NSCLC","Lung cancer","Chemotherapy","ADC","Antibody-Drug-Conjugate","Solid tumor","Phase 1","Ovarian neoplasms","Endometrial neoplasms","Carcinoma, Non Small Cell Lung","Lung neoplasms","Gynecologic cancer","EGFR Wt NSCLC","DNA Topoisomerase I","2026-03-26",{"date":304,"type":305},"2026-03-27","ACTUAL",{"date":307,"type":305},"2025-12-19",{"date":309,"type":271},"2028-12",{"name":5,"class":6},12]